DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Entry into a Material Definitive Agreement

Item1.01.

On February22, 2017, Delcath Systems, Inc. (the Company) and
holders of greater than 55% of the aggregate principal amount
(the Required Holders) of the Companys Senior Secured Convertible
Notes due December29, 2017 (the Notes) agreed to temporarily
reduce the conversion price for conversions at the option of the
holders of Notes (the Conversion Price) to $0.14 per share of the
Companys common stock, for a period commencing on February23,
2017 and ending on March2, 2017 (the Reduced Conversion Period).

The Required Holders also agreed to certain volume limitations on
sales of the Companys common stock thereby during the Reduced
Conversion Period.

The reduction of the Conversion Price may result in the issuance
of a substantial number of shares of the Companys common stock.
As of the close of business on February21, 2017, there were
40,049,740 shares of the Companys common stock outstanding.

About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Recent Trading Information

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) closed its last trading session up +0.018 at 0.188 with 27,578,166 shares trading hands.